MO13-2 Covalent FGFR Inhibitor Futibatinib Exhibits Sustained Antitumor Effects Compared with ATP-competitive Inhibitors

Futibatinib is a covalent FGFR1-4 inhibitor. In clinical trial, futibatinib demonstrated activity across a broad spectrum of FGFR-aberrant tumors, including FGFR2 fusion/rearrangement-positive cholangiocarcinoma. Some patients with acquired resistance to a prior FGFR inhibitor also experienced responses with futibatinib (Goyal et. al. Cancer Discovery 2022). In fact, futibatinib was active against multiple FGFR mutations conferring resistance to other FGFR inhibitors (Goyal et.al. Cancer Discovery 2019).